drugset / Trial / NCT00431951
Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers
Phase 1
Completed
30 enrolled
SIGA Technologies
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedFactorialDouble-blindTreatment
Summary
The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.
Timeline
- Start
- 2007-02
- Primary completion
- 2008-02
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tecovirimat | Small molecule | 250 mg | Oral |
| Subject | Tecovirimat | Small molecule | 400 mg | Oral |
| Subject | Tecovirimat | Small molecule | 800 mg | Oral |
Indications
No indication recorded.